Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Once-Daily MD-0901 (Mesalazine) in Mild to Moderate Ulcerative Colitis
jRCT2080221343Phase 3
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of Salcrozine in autoimmune colitis (2 arms), sponsored by Mochida Pharmaceutical Co., Ltd.
02
Drugs
Salcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080221343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221343.